Did Krug et al. find Pfizer Vaccine-Associated Myocarditis/Pericarditis in Adolescents using a Stratified Risk-Benefit Analysis? Yes, overwhelmingly in n=253 persons aged 12-17 years

In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates.

SOURCE:
https://onlinelibrary.wiley.com/doi/10.1111/eci.13759

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

‘Cases of myo/pericarditis (n = 253) included 129 after dose 1 and 124 after dose 2; 86.9% were hospitalized.
Incidence per million after dose two in male patients aged 12–15 and 16–17 was 162.2 and 93.0, respectively. Weighing post-vaccination myo/pericarditis against COVID-19 hospitalization during delta, our risk-benefit analysis suggests that among 12–17-year-olds, two-dose vaccination was uniformly favourable only in nonimmune girls with a comorbidity.
In boys with prior infection and no comorbidities, even one dose carried more risk than benefit according to international estimates.’
So then why did CDC lie in their MMWR reporting?

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander